Epistem Announces Research and Development Collaboration with Novartis
News Mar 03, 2009
Epistem Plc has announced that it has signed a research and development collaboration with Novartis to identify new drug targets and therapeutics across a variety of disease areas.
The collaboration combines Epistem’s stem cell expertise and drug discovery programme, with Novartis’s insights into disease pathways & bioinformatics.
Under the terms of the agreement, Novartis will pay Epistem an upfront cash payment of $4.0 million and will provide research funding for 2 years. Novartis has an option to exclusively license targets for development of biotherapeutic products in exchange for license fees, milestone payments and royalties.
For each product developed from targets licensed under the agreement, Epistem is eligible to receive up to $45.0 million in milestones. Furthermore, if leads are commercialized Epistem is eligible to receive tiered royalties on worldwide sales.
Matthew Walls, Epistem CEO, commented: “The collaboration will enable us to accelerate the development of our existing targets with a world class pharmaceutical collaborator and to jointly explore disease opportunities in regenerative medicine”.
Dr Jeffrey Moore, Novel Therapies Division Managing Director said: “The collaboration will leverage each group’s strengths to make novel discoveries leading to advances in treating unmet medical needs across several disease areas”.
An artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019